AmerisourceBergen Interview Highlights the Power of RWE in Drug Development Pipeline

A recent Fierce Biotech interview with AmerisourceBergen research experts focused on the role of real world evidence (RWE) in the drug development pipeline. In addition to improving the quality of conclusions drawn from clinical trials, researchers are increasingly turning to RWE in rare disease research.

Xcenda’s Vice President of Scientific Consulting Michael Eaddy remarks, “[F]or orphan diseases of the sample size of populations are just so small that randomization could be problematic and require for your trial to go over a longer period of time. Being able to select controls outside of your clinical trials has that potential to reduce time, cost, and the patient burden associated with clinical trials.” Read more here.

(Source: Fierce Biotech, 5/17/21)